Resources from the same session
2053 - Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)
Presenter: Michiel Van der Heijden
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
905PD - Multiple-cohort analysis investigating FGFR3 alteration as a predictor of non-response to neoadjuvant pembrolizumab (pembro) in muscle-invasive bladder cancer (MIBC)
Presenter: Andrea Necchi
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
4374 - Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: comprehensive tumor genomic and transcriptomic analyses
Presenter: Alain Ravaud
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4138 - ADAPTeR: A phase II study of anti-PD1 (nivolumab) therapy as pre- and post-operative therapy in metastatic renal cell carcinoma.
Presenter: Lewis Au
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4174 - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): subgroup analysis from the phase 3 JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)
Presenter: Laurence Albiges
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4707 - NIVOREN GETUG-AFU 26 translational study:CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N).
Presenter: Yann Vano
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
4823 - Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): subgroup analysis from the phase 3 JAVELIN Renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)
Presenter: Toni Choueiri
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
3170 - A First-in-Human Phase 1/2 Trial of the Oral HIF-2a Inhibitor PT2977 in Patients with Advanced RCC
Presenter: Eric Jonasch
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
3527 - Results of the Phase 2 TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 (TRAX) versus AXitinib (AX) Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (mRCC)
Presenter: Toni Choueiri
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract
3113 - APACHE: an open label, randomized, phase 2 study of Durvalumab (Durva), alone or in combination with Tremelimumab (Treme), in patients (pts) with refractory germ cell tumors (GCT): results from the expanded combination therapy cohort
Presenter: Elena Farè
Session: Poster Discussion – Genitourinary tumours, non-prostate
Resources:
Abstract